ESR1 and breast carcinoma: Among patients whose ctDNA was analyzed, all patients with breast cancer who had primary resistance to T-DM1 were ER positive and/or PR positive by IHC, and HER2 amplification-negative by analysis of ctDNA obtained just before initiation of T-DM1 treatment.